Disulfiram (DSF) has a long history of being used as a first-line promising therapy for treatment of alcoholism in human. Besides its prominence in the treatment of alcoholism, extensive investigations have been carried out to explore other biomedical and pharmacological effects of DSF. Amongst other biomedical implications, plenty researches have shown evidence of promising anticancer efficacy of this agent for treatment of wide range of cancers such as breast cancer, liver cancer and lung carcinoma.
Electronic databases, including Google scholar, PubMed and Web of science were searched with the keywords disulfiram, nanoparticles, cancer, drug delivery systems.
Despite its excellent anticancer efficacy, the pharmaceutical significance and clinical applicability of DSF are hampered due to poor stability, low solubility, short plasma half-life, rapid metabolism, and early clearance from systemic circulation. Various attempts have been made to eradicate these issues. Nanotechnology based interventions have gained remarkable recognition in improving pharmacokinetic and pharmacodynamic profile of DSF by improving its stability and avoiding its degradation.
The aim of the present review is to critically analyse all recent developments in designing various nanotechnology-based delivery systems, to ponder their relevance in improving stability, pharmacokinetic and pharmacodynamic profile, and achieving target-specific delivery of this agent to cancer cells to effectively eradicate cancer and abolish its metastasis. Nanotechnology is a novel approach for overcoming such obstacles faced presently, the results obtained so far using different novel drug delivery systems seem to be very promising to increase the stability and half-life of DSF.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–83.
Cvek B. Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram). Drug Discov Today. 2012;17(9–10):409–12.
Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res. 2005;11(3):971–81.
Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006;26(3):290–302.
Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. ActaPsychiatr. Scand. 1992;86(S369):15–26.
Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006;66(21):10425–33.
Dalla Pozza E, Donadelli M, Costanzo C, Zaniboni T, Dando I, Franchini M, et al. Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives. Free Radic Biol Med. 2011;50(8):926–33.
Kim SK, Kim H, Lee DH, Kim TS, Kim T, Chung C, et al. Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells. PLoS One. 2013;8(10):e78130.
Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer. 2012;107(9):1488–97.
Cen D, Brayton D, Shahandeh B, Meyskens FL, Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 2004;47(27):6914–20.
Liu P, Kumar IS, Brown S, Kannappan V, Tawari PE, Tang JZ, et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer. 2013;109(7):1876–85.
Abu-Serie MM, El-Rashidy FH. In vitro collapsing colon cancer cells by selectivity of disulfiram-loaded charge switchable nanoparticles against cancer stem cells. Recent Pat Anticancer Drug Discov. 2017;12(3):260–71.
You SY, Rui W, Chen ST, Chen HC, Liu XW, Huang J, et al. Process of immunogenic cell death caused by disulfiram as the anti-colorectal cancer candidate. Biochem Biophys Res Commun. 2019;513(4):891–7.
Duan L, Shen H, Zhao G, Yang R, Cai X, Zhang L, et al. Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells. Biochem Biophys Res Commun. 2014;446(4):1010–6.
Sharma V, Verma V, Lal N, Yadav SK, Sarkar S, Mandalapu D, et al. Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor—estrogen receptor β. Mol Carcinog. 2016;55(11):1843–57.
Spillier Q, Vertommen D, Ravez S, Marteau R, Thémans Q, Corbet C, et al. Anti-alcohol abuse drug disulfiram inhibits human PHGDH via disruption of its active tetrameric form through a specific cysteine oxidation. Sci Rep. 2019;9(1):4737.
Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, et al. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009;15(19):6070–8.
Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 2011;71(4):333–43.
Morrison BW, Doudican NA, Patel KR, Orlow SJ. Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. Melanoma Res. 2010;20(1):11–20.
Rae C, Tesson M, Babich JW, Boyd M, Sorensen A, Mairs RJ. The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells. J Nucl Med. 2013;54(6):953–60.
Yang Y, Deng Q, Feng X, Sun J. Use of the disulfiram/copper complex for breast cancer chemoprevention in MMTV-erbB2 transgenic mice. Mol Med Rep. 2015;12(1):746–52.
Cvek B. Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome. Curr Cancer Drug Tar. 2011;11(3):332–7.
Ekinci E, Rohondia S, Khan R, Dou QP. Repurposing Disulfiram as an anti-Cancer agent: updated review on literature and patents. Recent Pat Anticancer Drug Discov. 2019.
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–55.
Hu P, Jin L, Baillie TA. Studies on the metabolic activation of Disulfiram in rat. Evidence for electrophilic S-oxygenated metabolites as inhibitors of aldehyde dehydrogenase and precursors of UrinaryN-Acetylcysteine conjugates. J Pharmacol Exp Ther. 1997;281(2):611–7.
Wang W, Darling JL. How could a drug used to treat alcoholism also be effective against glioblastoma? Rev Anticancer Ther. 2013;13(3):239–41.
Liu P, Wang Z, Brown S, Kannappan V, Tawari PE, Jiang W, et al. Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo. Oncotarget. 2014;5(17):7471.
Löbler M, Rohm HW, Schmitz KP, Johnston AH, Newman TA, Ranjan S, et al. Drug delivery by nanoparticles—facing the obstacles. In4th European Conference of the In Fed for Med and Bio Eng 2009 (pp. 2335-2338). Springer, Berlin. Heidelberg. .
Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano. 2013;7(7):5858–69.
Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S, et al. Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram. Nanotechnology. 2014;25(12):125102.
Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41(7):2971–3010.
Burgess P, Hutt PB, Farokhzad OC, Langer R, Minick S, Zale S. On firm ground: IP protection of therapeutic nanoparticles. Nat Biotechnol. 2010;28(12):1267–70.
Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16–20.
Khalid M, El-Sawy HS. Polymeric nanoparticles: promising platform for drug delivery. Int J Pharm. 2017;528(1–2):675–91.
Lai P, Daear W, Löbenberg R, Prenner EJ. Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly (d, l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surf B Biointerfaces. 2014;118:154–63.
Zhuo X, Lei T, Miao L, Chu W, Li X, Luo L, et al. Disulfiram-loaded mixed nanoparticles with high drug-loading and plasma stability by reducing the core crystallinity for intravenous delivery. J Colloid Interface Sci. 2018;529:34–43.
Hoda M, Pajaniradje S, Shakya G, Mohankumar K, Rajagopalan R. Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line. Nanomed-Nanotechnol. 2016;12(6):1641–50.
Najlah M, Ahmed Z, Iqbal M, Wang Z, Tawari P, Wang W, et al. Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer. Eur J Pharm Biopharm. 2017;112:224–33.
He H, Markoutsa E, Li J, Xu P. Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly. Acta Biomater. 2018;68:113–24.
Song W, Tang Z, Shen N, Yu H, Jia Y, Zhang D, et al. Combining disulfiram and poly (l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance. J Control Release. 2016;231:94–102.
Song W, Tang Z, Lei T, Wen X, Wang G, Zhang D, et al. Stable loading and delivery of disulfiram with mPEG-PLGA/PCL mixed nanoparticles for tumor therapy. Nanomedicine. 2016;12(2):377–86.
Fasehee H, Zarrinrad G, Tavangar SM, Ghaffari SH, Faghihi S. The inhibitory effect of disulfiram encapsulated PLGA NPs on tumor growth: different administration routes. Mat Sci Eng C-Mater. 2016;63:587–95.
Hanumantha Rao Madala SR, Ali-Osman F, Zhang R, Srivenugopal KS. Brain-and brain tumor-penetrating disulfiram nanoparticles: Sequence of cytotoxic events and efficacy in human glioma cell lines and intracranial xenografts. Oncotarget. 2018;9(3):3459.
Fasehee H, Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Faghihi S. A comparative cytotoxic evaluation of disulfiram encapsulated PLGA nanoparticles on MCF-7 cells. Int J Hematol Oncol Stem Cell Res. 11(2):102.
Wang Z, Tan J, McConville C, Kannappan V, Tawari PE, Brown J, et al. Poly lactic-co-glycolic acid-controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine. 2017;13(2):641–57.
Tao X, Gou J, Zhang Q, Tan X, Ren T, Yao Q, et al. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core–shell–corona nanoparticles. Biomater Sci. 2018;6(7):1869–81.
Peng X, Pan Q, Zhang B, Wan S, Li S, Luo K, et al. Highly stable, coordinated polymeric nanoparticles loading copper (II) diethyldithiocarbamate for combinational chemo/chemodynamic therapy of cancer. Biomacromolecules. 2019;6:2372–83.
Miao L, Su J, Zhuo X, Luo L, Kong Y, Gou J, et al. mPEG5k-b-PLGA2k/PCL3. 4k/MCT mixed micelles as carriers of Disulfiram for improving plasma stability and antitumor effect in vivo. Mol. Pharm. 2018;15(4):1556–64.
Huo Q, Zhu J, Niu Y, Shi H, Gong Y, Li Y, et al. pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer. Int J Nanomedicine. 2017;12:8631.
Mohammad IS, He W, Yin L. A smart paclitaxel-disulfiram nanococrystals for efficient MDR reversal and enhanced apoptosis. Pharm. Res. 2018;35(4):77.
Mohammad IS, Teng C, Chaurasiya B, Yin L, Wu C, He W. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer. Int J Pharm. 2019;557:304–13.
Wang C, Yang J, Han H, Chen J, Wang Y, Li Q, et al. Disulfiram-loaded porous PLGA microparticle for inhibiting the proliferation and migration of non-small-cell lung cancer. Int J Nanomedicine. 2017;12:827.
Zhang L, Tian B, Li Y, Lei T, Meng J, Yang L, et al. A copper-mediated disulfiram-loaded pH-triggered PEG-shedding TAT peptide-modified lipid nanocapsules for use in tumor therapy. ACS Appl Mater Interfaces. 2015;7(45):25147–61.
Banerjee P, Geng T, Mahanty A, Li T, Zong L, Wang B. Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors. Int J Pharm. 2019;557:374–89.
Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8(24):1112–20.
Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv. 2010;1(2):323–34.
Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563–70.
Fasehee H, Dinarvand R, Ghavamzadeh A, Esfandyari-Manesh M, Moradian H, Faghihi S, et al. Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations. J Nanobiotechnol. 2016;14(1):32.
Deshmukh AS, Chauhan PN, Noolvi MN, Chaturvedi K, Ganguly K, Shukla SS, et al. Polymeric micelles: basic research to clinical practice. Int J Pharm. 2017;532(1):249–68.
Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv. 2013;13:340–415.
Yokoyama M. Clinical applications of polymeric micelle carrier systems in chemotherapy and image diagnosis of solid tumors. Med Sci Monit. 2011;3(4):151–8.
Farooq MA, Aquib M, Ghayas S, Bushra R, Haleem Khan D, Parveen A, Wang B. Whey protein: a functional and promising material for drug delivery systems recent developments and future prospects POLYM ADVAN TECHNOL. 2019.
Farooq MA, Aquib M, Khan DH, Ghayas S, Ahsan A, Ijaz M, et al. Nanocarrier-mediated co-delivery systems for lung cancer therapy: recent developments and prospects. Environ Chem Lett. 2019:1–9.
Wong CY, Al-Salami H, Dass CR. Microparticles, microcapsules and microspheres: a review of recent developments and prospects for oral delivery of insulin. Int J Pharm. 2018;537(1–2):223–44.
Kesharwani R, Sachan A, Singh S, Patel D. Formulation and evaluation of solid lipid nanoparticle (SLN) based topical gel of etoricoxib. J appl pharm sci. 2016;10:124–31.
Amol MP, Rohit RT, Dipak SG, Mohite SK, Magdum CS. A review on solid lipid nanoparticle. Res J of Pharm and Tech. 2016;8(3):218.
Declaration of interest
The authors state no conflict of interest and have received no funding in preparation of this manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Farooq, M.A., Aquib, M., Khan, D.H. et al. Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy. DARU J Pharm Sci 27, 853–862 (2019). https://doi.org/10.1007/s40199-019-00308-w